NCT02368301
No Longer Available
Not Applicable
An Expanded Access Program for Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Multiple Myeloma
- Sponsor
- Bristol-Myers Squibb
- Status
- No Longer Available
- Last Updated
- 2 years ago
Overview
Brief Summary
The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at U.S. sites where licensed physicians determine clinical need.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
No Longer Available
Not Applicable
Early Patient Access Treatment Use Protocol CA204-220Multiple MyelomaNCT02856438Bristol-Myers Squibb
No Longer Available
Not Applicable
Flotetuzumab Expanded Access ProgramAcute Myeloid LeukemiaAMLAML, Adult RecurrentNCT04678466MacroGenics
No Longer Available
Not Applicable
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple SclerosisMultiple SclerosisNCT02807285Genentech, Inc.
Unknown
Not Applicable
Early Patient Access Treatment Use Protocol CA204-220relapsed or refractory multiple myelomaJPRN-jRCT2080223322Bristol-Myers Squibb K.K.
Available
Not Applicable
Expanded Access to Telisotuzumab VedotinNon-Small Cell Lung Cancer (NSCLC)NCT04830202AbbVie